HYDERGINE
LOE ApproachingNDASUBLINGUALTABLET
Approved
Nov 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE is a sublingual small-molecule tablet approved in 1953 by Novartis with an unknown mechanism of action and indication profile. The drug's specific therapeutic target and patient population cannot be determined from available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), likely signaling a contracting commercial team focused on lifecycle extension and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYDERGINE currently has zero linked job openings, reflecting its mature, LOE-approaching lifecycle stage. Career opportunities are limited to defensive roles in commercial retention, generic transition planning, and market access management.
Brand ManagerMarket Access
Worked on HYDERGINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.